Business Context and Reporting Period
This Form 8-K, dated May 27, 2026, reports on National HealthCare Corporation (NHC), a Delaware corporation headquartered in Murfreesboro, Tennessee. The filing discloses the entry into a new Credit Agreement on May 26, 2026, and the termination of an existing credit facility. The primary purpose of the new financing is to support the acquisition of assets and real property from National Health Investors, Inc. (NHI), referred to as the "Transaction."
Key Financial Metrics and Debt Structure
The filing details a new senior unsecured credit facility with the following terms:
- Term Loan Facility: $475.0 million, structured as a single-draw facility.
- Revolving Credit Facility: $50.0 million, including a $5.0 million sublimit for letters of credit and a $15.0 million sublimit for swingline loans.
- Maturity: Five years from the Funding Date (anticipated Q3 2026).
- Amortization: Term loans amortize in quarterly installments of approximately $5.9 million; revolving loans require interest-only payments.
- Interest Rates: Variable rates based on Term SOFR or a base rate plus an applicable margin. Initial margins are expected to be Term SOFR + 1.50% or base rate + 0.50%.
- Commitment Fees: 0.20% to 0.30% per annum on the unused portion of the Revolving Facility.
- Covenants: Includes a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio.
The filing does not provide current revenue, profit, cash flow, or liquidity metrics for the reporting period, as this is a current report regarding a specific agreement rather than a periodic financial statement.
Material Changes Versus Prior Period
The most significant change is the replacement of NHC's existing credit facility (dated August 1, 2024) with the new Credit Agreement. As of March 31, 2026, there were no amounts outstanding under the existing facility, and NHC expects to repay any outstanding amounts under the old agreement simultaneously with the initial funding of the new facility. The new agreement increases NHC's total committed borrowing capacity to $525.0 million.
Guidance, Outlook, and Risks
Transaction Timeline: The Transaction and initial funding are expected to close in the third quarter of 2026, currently anticipated on or around July 1, 2026. This is subject to closing conditions, including the expiration of the Hart-Scott-Rodino Antitrust waiting period.
Conditions Precedent: If the Purchase and Sale Agreement is terminated, the Transaction closes without borrowing, or the Funding Date does not occur by August 31, 2026, the lenders' commitments under the new Credit Agreement will automatically terminate.
Risks and Contingencies: Management highlights significant risks, including the potential failure to satisfy closing conditions, unexpected costs or liabilities, regulatory changes in the healthcare industry, and changes in Medicare/Medicaid payment methodologies. The filing includes a standard caution regarding forward-looking statements, noting that actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the final closing date of the NHI asset acquisition and whether it occurs by the August 31, 2026 deadline.
- Confirm the actual drawdown amount under the $475.0 million Term Loan Facility upon funding.
- Monitor NHC's consolidated leverage ratio and fixed charge coverage ratio to ensure compliance with the new covenants.
- Review the final terms of the Purchase and Sale Agreement for any changes to the purchase price or asset scope.
- Assess the impact of the new debt service obligations (approx. $5.9 million quarterly amortization plus interest) on future cash flows.